Motley Fool38d agoneutral
Ocugen (OCGN) Q2 2026 Earnings Call TranscriptGene therapy developer advances three Phase III programs toward 2028 regulatory filings.
News
High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
79last 24h
964last 7d
110● bullish (7d)
116● bearish (7d)
212publishers
MarketBeat45d agoneutral
Ocugen Q2 Earnings Call HighlightsOcugen (NASDAQ:OCGN) said its second quarter marked progress across its late-stage ophthalmology pipeline, including FDA clearance to begin a Phase III study of OCU410 in geographic atrophy and an RMAT designation for the program. Chairman, Chief Executive Officer and Co-Founder Shankar Musunuri sa
GuruFocus.com45d agoneutral
Ocugen Inc (OCGN) (Q2 2026) Earnings Call Highlights: FDA Clearance for OCU410 Phase 3 Trial ...Ocugen Inc (OCGN) advances its gene therapy pipeline with key regulatory milestones and strategic partnerships, despite a wider net loss and delayed BLA submission.
Zacks108d agoneutral
Why Is Ocugen (OCGN) Down 10.7% Since Last Earnings Report?Ocugen (OCGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Insider Monkey131d agoneutral
Ocugen (OCGN) Reports Q1 EPSOcugen, Inc. (NASDAQ:OCGN) is one of the 10 Best Penny Stocks to Buy Before They Explode. On May 5, 2026, Ocugen, Inc. (NASDAQ:OCGN) reported Q1 EPS of (6c), versus the consensus estimate of (5c). Revenue totaled $1.53M, versus the consensus estimate of $358,140. Chairman, CEO, and Co-Founder Dr. Shankar Musunuri said the company completed enrollment […]
MarketBeat138d agoneutral
Ocugen Q1 Earnings Call HighlightsOcugen (NASDAQ:OCGN) used its first-quarter 2026 earnings call to highlight progress across its retinal gene therapy pipeline and to outline a strengthened balance sheet following a newly announced financing. Convertible notes offering and cash runway outlook Chairman, CEO, and Co-founder Dr. Shank